These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 20037974)

  • 1. [Thrombocyte control in bridging. Is it "evidence based" or "expert based"?].
    Jakobs C
    MMW Fortschr Med; 2009 Nov; 151(47):17; author reply 17. PubMed ID: 20037974
    [No Abstract]   [Full Text] [Related]  

  • 2. [Marcumarized patient must have surgery. Playing it safe with low molecular weight heparin bridging].
    MMW Fortschr Med; 2005 Jun; 147(22):51. PubMed ID: 15977637
    [No Abstract]   [Full Text] [Related]  

  • 3. [Are there guidelines for timing readministration of anticoagulation with marcumar in patients with artificial heart valves after intracerebral hemorrhage (stroke, subarachnoid hemorrhage, subdural hematoma)?].
    Kienast J; Ringelstein EB; Borggrefe M
    Internist (Berl); 1997 Jan; 38(1):83-5. PubMed ID: 9119665
    [No Abstract]   [Full Text] [Related]  

  • 4. [Are there guidelines for performance of coloscopy during drug anticoagulation?].
    Vogt W; Maier KP
    Dtsch Med Wochenschr; 2003 Oct; 128(44):2333. PubMed ID: 14593580
    [No Abstract]   [Full Text] [Related]  

  • 5. Bleeding complications in patients on anticoagulants who would have been disqualified for clinical trials.
    Levi M; Hovingh K
    Thromb Haemost; 2008 Dec; 100(6):1047-51. PubMed ID: 19132229
    [No Abstract]   [Full Text] [Related]  

  • 6. How useful is determination of anti-factor Xa activity to guide bridging therapy with enoxaparin? A pilot study.
    Hammerstingl C; Omran H; Tripp C; Poetzsch B
    Thromb Haemost; 2009 Feb; 101(2):325-32. PubMed ID: 19190817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Heparin-induced thrombosis-thrombocytopenia syndrome in Crohn disease. Further thromboses with oral anticoagulation after discontinuation of heparin].
    Eisenlohr H; Trenkwalder P; Lydtin H
    Internist (Berl); 1992 Jun; 33(6):432-4. PubMed ID: 1352765
    [No Abstract]   [Full Text] [Related]  

  • 8. Recommendations on bleeding and nonbleeding complications of vitamin K antagonists.
    Ansell J
    Clin Adv Hematol Oncol; 2007 Jul; 5(7):517-8, 554. PubMed ID: 17679924
    [No Abstract]   [Full Text] [Related]  

  • 9. [Use of LMW heparin: information for prescribers. Update: 10 April 2002].
    Agence Française de Sécurité Sanitaire Des Produits de Santé (AFSSAPS)
    J Mal Vasc; 2002 Oct; 27(4):231-3. PubMed ID: 12457130
    [No Abstract]   [Full Text] [Related]  

  • 10. Guidelines for antithrombotic therapy: periprocedural management of antithrombotic therapy and use of bridging anticoagulation.
    Spyropoulos AC; Douketis JD
    Int Angiol; 2008 Aug; 27(4):333-43. PubMed ID: 18677297
    [No Abstract]   [Full Text] [Related]  

  • 11. [Anticoagulation for difficult cases].
    Fischer A
    MMW Fortschr Med; 2009 Jun; 151(24):18-9. PubMed ID: 19645194
    [No Abstract]   [Full Text] [Related]  

  • 12. Recognition, treatment, and prevention of heparin-induced thrombocytopenia: review and update.
    Greinacher A; Warkentin TE
    Thromb Res; 2006; 118(2):165-76. PubMed ID: 16139874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pronounced phenprocoumon overdosage as a consequence of an unclear physician's order].
    Schaer B
    Dtsch Med Wochenschr; 1996 Jul; 121(27):887. PubMed ID: 8681749
    [No Abstract]   [Full Text] [Related]  

  • 14. [Heparin-induced thrombocytopenia type II: a clinically relevant problem?].
    Böck M; Woitzyk I; Jepsen MS; Molling J; Welte T; Leimkühler K; Heim MU
    Beitr Infusionsther Transfusionsmed; 1997; 34():273-5. PubMed ID: 9417348
    [No Abstract]   [Full Text] [Related]  

  • 15. Concomitant antiplatelet and anticoagulation therapy: indications, controversies and practical advice.
    Dowd M
    Thromb Res; 2008; 123 Suppl 1():S11-5. PubMed ID: 18822448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [How should anticoagulants be used in recurrent, ischemic and hemorrhagic brain infarctions?].
    Leschke M; Klimek W
    Dtsch Med Wochenschr; 2003 Oct; 128(42):2213-4. PubMed ID: 14562222
    [No Abstract]   [Full Text] [Related]  

  • 17. The timing of a positive test result for heparin-induced thrombocytopenia relative to the platelet count and anticoagulant therapy in 43 consecutive cases.
    Refaai MA; Van Cott EM; Laposata M
    Am J Clin Pathol; 2003 Apr; 119(4):497-504. PubMed ID: 12710122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding low INR in clinical practice.
    Hylek EM; Rose AJ
    Thromb Haemost; 2009 Mar; 101(3):417-8. PubMed ID: 19277399
    [No Abstract]   [Full Text] [Related]  

  • 19. Role of prostacyclin (epoprostenol) as anticoagulant in continuous renal replacement therapies: efficacy, security and cost analysis.
    Gainza FJ; Quintanilla N; Pijoan JI; Delgado S; Urbizu JM; Lampreabe I
    J Nephrol; 2006; 19(5):648-55. PubMed ID: 17136695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse reactions to anticoagulants and to antiplatelet drugs recorded by the German spontaneous reporting system.
    Tiaden JD; Wenzel E; Berthold HK; Müller-Oerlinghausen B
    Semin Thromb Hemost; 2005; 31(4):371-80. PubMed ID: 16149013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.